chromosome 11 open reading frame 16Genealiases: []
Q-omics provides the consensus-scored C11orf16 profile across patient tissues and cancer cell-line models. C11orf16 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, C11orf16 is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, C11orf16 RNA expression shows 14,503 significant gene co-expression associations, with the highest sampling consensus in LAML. Together, these results highlight LIHC, KIRC, and LAML as cancer lineages where C11orf16 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for C11orf16 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes C11orf16 survival associations across molecular data types. C11orf16 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible C11orf16 RNA expression–survival associations across cancer types. High C11orf16 expression shows unfavorable associations in LIHC and MESO, but favorable associations in SKCM, LUAD, HNSC and BRCA. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for C11orf16 RNA expression.
This table summarizes C11orf16 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 2. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for C11orf16. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. C11orf16 shows lower tumor expression in KIRC, LUSC, LUAD, KIRP and KICH and higher tumor expression in LIHC. The KIRC box plot shows higher C11orf16 RNA expression in normal versus tumor tissue (log2 FC = −0.631, t-test p < 0.001).
This table shows molecular features associated with C11orf16 in patient tissues and cancer cell lines. In patient samples, C11orf16 shows the broadest associations at the RNA and protein expression levels, with LAML recurring as the lineage with the largest associated feature set. In cancer cell lines, C11orf16 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BONE.
